Objectives: To directly measure the cervico-vaginal lavage (CVL) and plasma PRO 2000 concentrations achieved by vaginal dosing.
Introduction
Vaginal microbicides are under active investigation to attempt to develop new female-controlled HIV prevention strategies [1] . Candidate compounds that can block HIV transmission are identified in vitro, and studied in animal models for safety and potential efficacy. PRO 2000, a naphthalene sulphonate polymer, is one of a number of polyanionic compounds (e.g. Carraguard; cellulose sulphate, cellulose acetate phthalate) in development as topical microbicides. PRO 2000 and other polyanions may prevent HIV infection through interference with gp120-CD4 interactions, post-binding events/ virus-cell fusion, and dissemination pathways [Fowler KE, Parise M, the Microbicide Development Programme, UK, and Sattentau Q J (in preparation), and Shattock RJ, personal communication]. PRO 2000 has been shown to be effective in blocking HIV transmission in both the cervical explant model [2] and a macaque model for vaginal HIV transmission [3] . In the macaque model PRO 2000 0.5, 2 and 4% gels were all shown to be effective.
The dose or concentration of the active agent to be used in early safety studies in women is generally chosen empirically, based on previous laboratory and animal studies. We have reported a phase I trial in sexually inactive women of PRO 2000, which was generally well tolerated, with promising local and systemic safety profiles [4] . We wished to investigate possible systemic absorption of PRO 2000, and also determine the concentrations of PRO 2000 achieved in cervico-vaginal secretions during regular vaginal administration.
Materials and methods
At one of the two centres in the published study [4] , St Mary's Hospital, London, a sub-study was performed to directly evaluate the levels of PRO 2000 in the genital tract achieved by initial and then regular intravaginal dosing between menses. Women were screened for genital tract infections at study entry. Thirty-six subjects were enrolled to this randomized, double-blind study and received placebo gel (n ¼ 12), 0.5% PRO 2000 gel (n ¼ 12) or 4% PRO 2000 gel (n ¼ 12). All the gels were based on Carbopol 1382 and had identical components except for the PRO 2000, and were identical in appearance [5] . Two 2 g (approximately 2 ml) doses of the microbicide were self administered on the first study day and a single dose on each of the subsequent 12 days. Participants were instructed to refrain from sexual intercourse during the dosing period. Two hours after the first dose and approximately 12 h after the seventh dose, a cervico-vaginal lavage (CVL) was performed by instilling 5 ml sterile normal saline into the vagina, and after 1 min, aspirating the pooled fluid using a syringe and quill. Plasma samples were obtained before and 2 h after the first dose, and approximately 12 h and 8 days after the fourteenth dose. Plasma and CVL specimens were stored at À208C until analysis. PRO 2000 concentrations were assayed by high performance liquid chromatography (HPLC) with fluorescence detection. The method was validated for determination of PRO 2000 concentrations ranging from 16 to 800 mg/ml in CVL, and 1.0 to 25 mg/ml in plasma.
Cervico-vaginal lavage results in the dilution of cervicovaginal secretions. Different studies have used different volumes of instilled lavage fluid but we used a lavage volume of 5 ml. Microbicides are designed to block HIV transmission during and after coitus with male ejaculation. The normal volume of an ejaculate varies from 2 to 6 ml [5] . As the lavage volume we used is similar to the maximal ejaculatory volume, we assume in this paper that the measured PRO 2000 concentrations in the CVL sample are representative of the concentrations that would be seen in cervico-vaginal secretions post-coitus with ejaculation.
The effect of PRO 2000 in blocking HIV infection has been investigated in the cervical explant model [2] . In separate experiments involving one M-tropic laboratoryadapted isolate and three primary isolates, PRO 2000 at a concentration of 100 mg/ml completely inhibited proviral DNA formation and p24 production. Further data from this study showed that at 10 mg/ml 70% protection of the explant against infection by HIV-1 Ba-L was seen, and at 1 mg/ml 20% protection was seen (Shattock RJ, personal communication). Extrapolating from this data, we have chosen a level of 25 mg/ml as representing a target concentration for PRO 2000 in cervico-vaginal secretions that would be necessary to block HIV transmission.
We also estimated the proportion of the administered dose of microbicide recovered by the CVL sampling. The upper vagina and cervix have complex anatomical topography, which is not completely exposed by an opened speculum, and this caused some performance variability in the recovery of the CVL sample. We therefore assume that 5 ml of CVL were recovered in each subject and calculate the proportion of administered dose recovered as: mean PRO 2000 concentration (mg/ml) Â 5 ml/administered dose [80 mg for PRO 2000 4% and 10 mg for PRO 2000 0.5%].
Results
Firstly, PRO 2000 was not detected in any plasma sample from any group. Secondly, PRO 2000 was not detected in any CVL sample from the placebo gel group. The results of the assays performed on CVLs for the 4 and 0.5% groups are displayed in Table 1 .
From Table 1 it can be seen that at the 2 h post-first dose sampling all individual samples from both the 4% group and the 0.5% group exceeded the CVL target concentration. However, the mean PRO 2000 level in the 4% group exceeded the CVL target concentration by 155-fold whereas the mean level in the 0.5% group was 5.3-fold the target concentration. At the 12 h post-day 6 dose, the sampling CVL levels from 10 of 12 of the 4% PRO 2000 group individuals and five of 12 of the 0.5% group exceeded the CVL target concentration. Furthermore, at 12 h after the day 6 dose, the mean PRO 2000 CVL level of the 4% group exceeded the target concentration by 123-fold whereas the mean CVL level in the 0.5% group was 1.4-fold the target concentration.
For the 2 h post-first dose sampling the proportion of the administered dose recovered was 22% for the 4% PRO 2000 gel group and 6.7% for the 0.5% gel group. At the 12 h post-day 6 dose the proportion recovered was 19% for the 4% gel group and 1.8% for the 0.5% gel group.
Discussion
There are no previous published studies of vaginal microbicides in which the local and systemic concentrations of the active agent achieved by vaginal dosing have been measured directly. There has been one other study in which cervico-vaginal concentrations of PRO 2000 0.5% gel were measured 1 h after dosing [6] and these data are entirely in keeping with our observations. There was no evidence of systemic absorption of PRO 2000 from vaginal administration of 0.5 or 4% gel within the study schedules. It should be noted these were young, healthy, fertile women, neither sexually active nor menstruating, and whether systemic absorption could take place in other contexts was not assessed.
In vivo in women 4% PRO 2000 gel achieved substantially higher levels of PRO 2000 in CVL at 2 h post-first dose than 0.5% gel. However, CVL levels in all women in both the 4 and 0.5% groups achieved the target concentration at this time point. At the 12 h post-day 6 dose 10 of 12 of the women in the 4% gel group achieved the target concentration in comparison with five of 12 of women in the 0.5% group. The measured concentrations could be underestimates of the amount of PRO 2000 present within the genital tract. A proportion of the persisting intravaginal PRO 2000 might not be mobilized or accessed by the lavage (e.g. high the vaginal fornices), or might adhere tightly to the cervico-vaginal epithelium. Such residual reservoirs would still contribute to antiviral activity. Dosing with PRO 2000 4% gel was also associated with detection of a greater proportion of the administered dose of PRO 2000 compared with 0.5% gel, both after the first dose and especially after repeat dosing. Another study examined the proportional recovery of Nonoxynol-9 (N-9) after single dosing with different N-9 preparations and reported a range of proportional recoveries of the administered dose at 2 h from 19 to 6.6%, which is similar to our findings [7] . Possible explanations for the differential recovery of PRO 2000 between the two gels with different concentrations include non-specific binding of a fraction of the applied dose to the surface of the cervico-vaginal epithelium, or enzymatic digestion by biological factors, or other degradation in the vaginal milieu affecting the lower dose disproportionately.
Vaginally administered compounds can be taken up into the cervico-vaginal epithelium [8] . The vaginal epithelium possesses an elaborate system of intercellular channels, which are hormone-responsive [9] . PRO 2000 is a watersoluble polymer of molecular weight 5 kDa, and such compounds can also be taken up into epithelia by pinocytosis. Therefore, in the case of the multi-layered vaginal epithelium either of these processes might result in sequestration of PRO 2000 within the epithelium without systemic absorption [8] . In view of the mechanism of action of PRO 2000 which blocks HIV-target cell interactions it would therefore be beneficial if significant concentrations of PRO 2000 were present within the vaginal epithelium as well as in the luminal secretions.
Our data reflect recent observations arising from microbicide efficacy studies in macaque simian-human immunodeficiency virus transmission models. In recent experiments involving a variety of microbicidal agents including a monoclonal antibody (b12) [10] , PSC-RANTES [11] , and cyanovirin-N [12] , the administered concentrations necessary to block vaginal transmission exceeded the in-vitro inhibitory concentrations by 10 3 (b12, 75% inhibition of vaginal transmission), 10 4 (cyanovirin-N, 85% inhibition), and 10 6 (PSC-RANTES, 100% inhibition). Our data shows that within the human female lower genital tract at least a 1000-fold dilution of the in-vitro microbicidal activity occurs purely through normal anatomic and physiologic effects, and that decisions regarding human efficacy studies should take these factors into account.
Indeed, there are further factors that may operate during human sexual intercourse which could affect the concentrations and activity of microbicides necessary to block HIV transmission in vivo. Such factors include the effects of coitus in causing microtrauma to the female genital tract [13] , and mechanical effects of ejaculation causing high local concentrations of input virus in the endocervix [14] . It could be that under certain conditions such as in young female adolescents, in post-menopausal women, or when there is significant inflammation or disruption of the cervico-vaginal epithelium, target cells for HIV are either more susceptible to HIV infection or present in increased numbers. If PRO 2000 is to be successful in blocking HIV transmission in such 'field conditions' it will do so through activity in the cervicovaginal lumen or epithelium which our data gives support to. Therefore the design of our trial could be replicated with even higher administered concentrations of PRO 2000 to explore whether higher in-vivo concentrations or a ceiling of PRO 2000 activity can be achieved before adverse effects, such as irritation and inflammation are induced. The finding that an HIV-inhibitory concentration of PRO 2000 in CVL was maintained 12 hours postrepeated dosing in 81% of subjects in women in the 4% gel group and 42% of women in the 0.5% group is encouraging in terms of potential effectiveness in vivo. The very substantial excess in levels achieved by the 4% concentration is suggestive that higher concentrations of PRO 2000 gel may offer greater assurance of protection against HIV transmission in the context of human sexual intercourse provided that safety and acceptability issues are equivalent across the dosage range under consideration.
